Summary of Key Points Core Viewpoint - The week of May 6 to May 11 saw the acceptance of 2 new IPO applications in the Shanghai and Shenzhen stock exchanges, while 2 companies withdrew their IPO applications, and 1 company received registration approval. Group 1: New IPO Applications - Two new IPO applications were accepted on May 9, including Ningbo Jianxin Superconducting Technology Co., Ltd. for the Shanghai Stock Exchange's Sci-Tech Innovation Board and Hangzhou Lianchuan Biotechnology Co., Ltd. for the Beijing Stock Exchange [1][3] - Jianxin Superconducting is the third company accepted for the Sci-Tech Innovation Board this year, focusing on the R&D, production, and sales of core components for MRI equipment [3] - Jianxin Superconducting reported revenues of 359 million yuan, 451 million yuan, and 425 million yuan for 2022 to 2024, with net profits of 34.63 million yuan, 48.73 million yuan, and 55.78 million yuan respectively [3][4] - Lianchuan Biotechnology previously attempted to list on the Sci-Tech Innovation Board but withdrew its application and is now seeking to raise 300 million yuan, half of its previous target [4] Group 2: Terminated IPO Applications - Two companies withdrew their IPO applications: Wuxi Yelong Precision Machinery Co., Ltd. and Shenzhen Haobo Window Control Technology Co., Ltd. [1][6] - Wuxi Yelong, which specializes in turbocharger components, withdrew its application over a year after approval due to the impact of electric vehicles on its business [6][7] - Haobo Window Control reported a revenue decline of 2.46% in the first half of 2024 and expects a full-year revenue drop of 10.76% to 12.68% [8]

Group 1: Ningbo Jianxin Superconducting Technology Co., Ltd. IPO - The company is primarily engaged in the research, production, and sales of core components for medical magnetic resonance imaging (MRI) equipment, with a mission to make MRI accessible for everyday diagnosis [5][6] - The company reported a revenue of 425.50 million yuan in 2024, a decrease from 450.64 million yuan in 2023, while the net profit attributable to the parent company increased to 50.27 million yuan [8][9] - The company has a strong customer base, with the top five clients contributing over 73% of total revenue, including major players like Fujifilm and GE Healthcare [5][6][8] - The company plans to raise 865 million yuan through its IPO, with funds allocated for projects including the production of superconducting magnets and technological upgrades [12] Group 2: Hangzhou Lianchuan Biotechnology Co., Ltd. IPO - The company focuses on gene technology, providing various gene testing services primarily to universities and research institutions [15][16] - The company achieved a revenue of 366.76 million yuan in 2024, up from 286.59 million yuan in 2023, with a net profit of 56.66 million yuan [18][19] - The company plans to raise 300 million yuan through its IPO, with funds directed towards expanding its gene technology service platform and developing molecular diagnostic reagents [21][22] - The company faces risks due to its reliance on Illumina, a major supplier that has been placed on an unreliable entity list, which could impact its operations if supply issues arise [23][25]